載入中
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
前收盤價
US$7.63
+US$0.09 · +1.19%
盤後
US$7.63
US$0.00 · 0.00%
10月7日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
日內區間
目前US$7.63
52週區間
目前US$7.63
盤中時間採用ET。市場資料可能有所延遲。
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
日內區間
目前US$7.63
52週區間
目前US$7.63
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 5087 USD | 2萬 USD | 5281.5 USD | 373.4萬 USD | 16.69萬 USD |
| 毛利 | −5087 USD | −2萬 USD | −5281.5 USD | −373.4萬 USD | −16.69萬 USD |
| 研究與開發 | 1842.6萬 USD | 1365.88萬 USD | 664.63萬 USD | 373.4萬 USD | 200.36萬 USD |
| 銷售、一般及管理費用 | 743.8萬 USD | 516.24萬 USD | 456.73萬 USD | 469.4萬 USD | 262.43萬 USD |
| 營業費用 | 2645.9萬 USD | 1937.58萬 USD | 1165.61萬 USD | 469.4萬 USD | 462.79萬 USD |
| 利息收入 | 136萬 USD | 95.53萬 USD | 100.48萬 USD | 6.3萬 USD | 6263 USD |
| 利息支出 | — | — | 13.34萬 USD | — | 77.28萬 USD |
| 折舊和攤銷 | 4000 USD | 1.39萬 USD | 5276 USD | 31.97萬 USD | 16.2萬 USD |
| 營業利益 | −2645.9萬 USD | −1937.58萬 USD | −1165.61萬 USD | −842.8萬 USD | −664.79萬 USD |
| 淨利 | −2487.3萬 USD | −1957.86萬 USD | −1197.72萬 USD | −1132.2萬 USD | −1550.57萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
